GenOway expands its strategic plan with ROUTE50+DATA

On December 16, 2025, genOway announced the expansion of its ROUTE50+ strategic plan to ROUTE50+DATA. The acquisition of data science and AI assets from an OMICS platform strengthens its ambition in the predictability of preclinical data. This acquisition, financed by a €7 million private placement, accelerates the initial project by one year.

genOway has achieved its initial ROUTE50+ objectives, including the transformation of its organization and the launch of new preclinical model lines. The plan anticipates organic growth of 20% per year to reach €50 million in sales by 2028. With ROUTE50+DATA, genOway is developing new tools to improve pharmaceutical research, with revenue expected as early as 2026.